课题基金 / 基金详情

NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance

NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
胶质母细胞瘤肿瘤生长和治疗耐药性中的 NAD 通路信号传导
批准号:
10654813
负责人:
Albert Hong-Jae Kim
金额:
$44.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-07-01 至 2025-06-30

项目摘要

项目成果

Albert Hong-Jae Kim的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Glioblastoma, the most common primary malignant brain tumor in adults, remains incurable despite multimodal therapy, necessitating the discovery of new therapeutic strategies. Emerging evidence indicates that the unique metabolic profile of cancer cells interfaces with signal transduction and transcriptional programs to stimulate malignant behavior. Nicotinamide adenine dinucleotide (NAD+) plays a pivotal role in cancer cell metabolism, but how NAD+ and its regulation impacts functionally relevant signaling events in glioblastoma has not been well understood. We recently found that high expression of NAMPT, the rate-limiting step in NAD+ biosynthesis, in glioblastoma tumors is associated with poor overall survival in patients and demonstrated that NAMPT is essential for self-renewal and in vivo tumor growth in primary glioblastoma cells, indicating a requirement for NAD+ to maintain malignant behavior. We also identified a NAD+-dependent transcriptional program mediated by transcription factor E2F2, which is required for the self-renewal and clonogenic survival of glioblastoma cells. In this project, we will first elucidate the molecular mechanisms that link NAD+ to the E2F2-dependent transcriptional program in glioblastoma. We will then examine the role of NAD+ generation in glioblastoma cells focusing on NAMPT regulation, with examination of metabolic correlates using human tumor samples. Finally, we will investigate the ability of NAMPT inhibition in vivo to enhance the therapeutic efficacy of radiation therapy, a major arm of the current standard-of-care, and further delineate the mechanism by which NAMPT dictates radiation responsiveness. The immediate goal of this project is to identify the mechanisms of NAD+-dependent metabolic reprogramming in glioblastoma, with the long-term goal of developing novel NAD+ pathway-directed strategies to disrupt glioblastoma growth and increase the effectiveness of current therapies.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s10555-022-10051-5
发表时间: 2022-12
期刊: Cancer metastasis reviews
影响因子: --
作者: []
通讯作者:
Mechanisms of SOX2 Regulation in Glioblastoma
  • 批准号:
    10504032
  • 项目类别:
  • 资助金额:
    $37.64万
  • 财政年份:
    2022
  • 负责人:
    Albert Hong-Jae Kim
  • 依托单位:
Mechanisms of SOX2 Regulation in Glioblastoma
  • 批准号:
    10676179
  • 项目类别:
  • 资助金额:
    $38.22万
  • 财政年份:
    2022
  • 负责人:
    Albert Hong-Jae Kim
  • 依托单位:
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
  • 批准号:
    10448244
  • 项目类别:
  • 资助金额:
    $47.81万
  • 财政年份:
    2019
  • 负责人:
    Albert Hong-Jae Kim
  • 依托单位:
NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance
  • 批准号:
    10194624
  • 项目类别:
  • 资助金额:
    $45.47万
  • 财政年份:
    2019
  • 负责人:
    Albert Hong-Jae Kim
  • 依托单位:
海外基金